

[SGO 2022 Annual Meeting Full Schedule](#)

[SGO 2022 Annual Meeting Printable Schedule](#)

ON DEMAND SYMPOSIUM: Can You Take the Heat? HIPEC In Ovarian Cancer

PRESENTATIONS:

1. IMPLEMENTING HIPEC IN PRACTICE & BUILDING A HIPEC TEAM

Speaker: Michael G Kelley, MD

2. PICPAC – THE NEXT FRONTIER

Speaker: Thanh Dellinger, MD

3. INTRAOPERATIVE AND POSTOPERATIVE CONSIDERATIONS

Speaker: Leslie Randall, MD, MAS

4. APPLICATION AND EVIDENCE FOR HIPEC IN THE TREATMENT OF OVARIAN CANCER

Panel Discussion: Oliver Zivanovic, MD

ON DEMAND SYMPOSIUM: Curriculum for Emerging Clinical Trialists

PRESENTATIONS:

1. REGULATORY APPROVAL

Speaker: Bradley J Monk, MD, FACS, FACOG

2. GOG PARTNERS

Speaker: Thomas Herzog, MD

3. NRG

Speaker: Elise C. Kohn, MD

ON DEMAND SYMPOSIUM: Seminal Abstracts: The Best of ASCO, ESMO, IGCS and ESGO

PRESENTATIONS:

1. PHASE III DOUBLE-BLIND KEYNOTE-826 TRIAL PEMBROLIZUMAB FOR PERSISTENT, METASTATIC OR RECURRENT CERVICAL CANCER

Speaker: Nicoletta Colombo, MD, PhD

2. EMPOWER-CERVICAL 1/GOG/ENGOT-CX9: RESULTS OF PHASE III TRIAL OF CEMIPIMAB VS INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT/METASTATIC CERVICAL CARCINOMA

Speaker: Krishnansu S. Tewari, MD, FACOG, FACS, FRSM

3. DISTILLATION

Speaker: Bradley J. Monk, MD, FACS, FACOG

4. OREO/ENGOT OV-38: A PHASE IIIB TRIAL OF OLAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH EPITHELIAL OVARIAN CANCER

Speaker: Eric Pujade-Lauraine, MD, PhD

5. DISTILLATION

Speaker: Stephanie Gaillard, MD, PhD

6. TISOTUMAB VEDOTIN (TV) + CARBOPLATIN (CARBO) IN FIRST-LINE (1L) OR + PEMBROLIZUMAB (PEMBRO) IN PREVIOUSLY TREATED (2L/3L) RECURRENT OR METASTATIC CERVICAL CANCER (R/MCC): INTERIM RESULTS OF ENGOT-CX8/GOG-3024/INNOVATV 205 STUDY

Speaker: Domenica Lorusso, MD, PhD

7. ASSOCIATION OF HOMOLOGOUS RECOMINGATION DEFICIENCY (HRD) WITH CLINICAL OUTCOMES IN A PHASE III STUDY OF OLAPARIB OR CEDIRANIB AND OLAPARIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY IN RECURRENT PLATINUM-SENSITIVE OVARIAN CANCER (PSOC): BIOMARK

Speaker: Joyce F. Liu, MD MPH

8. MIRVETUXIMAP SORVATANSINE, A FOLATE RECEPTOR ALPHA-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH PLATINUM-AGNOSTIC OVARIAN CANCER: FINAL ANALYSIS

Speaker: David M. O'Malley, MD

9. MAINTENANCE VIGIL IMMUNOTHERAPY IN NEWLY DIAGNOSED ADVANCED OVARIAN CANCER: EFFICACY ASSESSMENT OF HOMOLOGOUS RECOMBINATION PROFICIENT (HRP) PATIENTS IN THE PASE IIB VITAL TRIAL

Speaker: Rodney P. Rocconi, MD

ON DEMAND SYMPOSIUM: SGO Business Meeting

PRESENTATIONS:

1. BUSINESS MEETING REPORT

Speaker: Seiko D. Yamada, MD

2. NOMINATING COMMITTEE REPORT

Speaker: David E. Cohn, MD, MBA

3. GOG REPORT

Speaker: Larry J. Copeland, MD

SPECIAL INTEREST SESSION: Master Class: Breaking Barriers:
Developing World Class Clinical Research Programs & Closing the Diversity Gap

Friday, March 18, 8:00 AM – 12:00 PM

PRESENTATIONS:

- 1. CREATING A “CULTURE OF RESEARCH”: PROGRAMMATIC BARRIERS**
Speaker: Stephanie Gaillard, MD, PhD
- 2. CREATING A “CULTURE OF RESEARCH”: COST CONSIDERATIONS**
Speaker: Robert L. Coleman, MD
- 3. CREATING A “CULTURE OF RESEARCH”: INTEGRATION INTO CLINICAL PRACTICE: LESSONS FROM COACH K**
Speaker: Angeles Alvarez Secord, MD
- 4. CREATING A “CULTURE OF RESEARCH”: PRIVATE PRACTICE CONSIDERATIONS**
Speaker: Colleen C. McCormick, MD, MPH
- 5. PROJECT ECHO, FOSTER TRIAL**
Speaker: Ursa A. Brown-Glaberman, MD
- 6. ENDOMETRIAL SOMATIC PROFILE DIFFERENCES BY RACE: A FIRST STEP TO NARROW THE DISPARITY GAP**
Speaker: Jennifer C. Gordon, MD
- 7. IMPACT OF DISPARITIES IN GENOMIC RESEARCH ON CLINICAL RESEARCH**
Speaker: Melissa B. Davis, PhD
- 8. LEVELING THE PLAYING FIELD: IDENTIFYING BARRIERS AND PATTERNS OF ENDOMETRIAL CANCER CLINICAL TRIAL ENROLLMENT FOR UNDERREPRESENTED GROUPS**
Speaker: Sarah S. Lee, MD, MBA
- 9. CRITICAL DECISIONS: A MIXED-METHODS STUDY INVESTIGATING DECISION-MAKING AND DISPARITIES AMONG DIVERSE GYNECOLOGIC CANCER PATIENTS CONSIDERING THERAPEUTIC CLINICAL TRIAL ENROLLMENT**
Speaker: Stephanie Rieder, MD, PhD
- 10. A COLLABORATIVE APPROACH TO ENGAGING AMERICAN INDIANS OF SOUTHWESTERN TRIBAL NATIONS IN CLINICAL RESEARCH INITIATIVES**
Speaker: Andrew L. Sussman, PhD, MCRP
- 11. ENHANCING MINORITY PARTICIPATION IN CLINICAL TRIALS: STRATEGIES FROM THE EMPACT CONSORTIUM AND NRG ONCOLOGY**
Speaker: Jennifer Wenzel, PhD, RN, CCM, FAAN

SCIENTIFIC PLENARY II: Building Bridges - Pioneering Protocols and Scientific Progress

Friday, March 18, 3:10 PM – 4:45 PM

PRESENTATIONS:

- 1. LONG TERM SURVIVAL OF GOG 252 “RANDOMIZED TRIAL OF INTRAVENOUS VERSUS INTRAPERITONEAL CHEMOTHERAPY PLUS BEVACIZUMAB IN ADVANCED OVARIAN CARCINOMA: AN NRG ONCOLOGY/GOG STUDY”**
Speaker: Joan L. Walker, MD
- 2. WHAT’S NEXT AFTER BEVACIUMB RESISTANCE? TARGETING METABOLIC VULNERABILITIES IN OVARIAN CANCER**
Speaker: Deanna Glassman, MD
- 3. PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, KEYNOTE-826 TRIAL OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER**
Speaker: Bradley J. Monk, MD, FACS, FACOG
- 4. SAFETY AND IMMUNOGENICITY OF ANTI PD-L1 (ATEZOLIZUMAB) GIVEN AS AN IMMUNE PRIMER OR CONCURRENTLY WITH EXTENDED FIELD CHEMORADIO THERAPY FOR NODE POSITIVE LOCALLY ADVANCED CERVICAL CANCER: AN NRG OCOLOGY TRIAL**
Speaker: Jyoti Mayadev, MD
- 5. PEMBROLIZUMAB FOR PERSISTEN, RECURRENT, OR METASTATIC CERVICAL CANCER: A COST-EFFECTIVENESS ANALYSIS**
Speaker: David A. Barrington, MD
- 6. DISTILLATION**
Speaker: Leslie Randall, MD, MAS
- 7. FINAL OVERALL SURVIVAL RESULTS FROM SOLO3: PHASE III TRIAL ASSESSESSING OLAPARIB MONOTHERAPY VESUS NON-PLATINUM CHEMOTHERAPY IN HEAVILY PRETREATED PATIENTS WITH GERMLINE BRCA1 AND/OR BRCA2-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER**
Speaker: Richard T Penson, MD
- 8. INVESTIGATION OF PARP INHIBITOR RESISTANCE THROUGH THE ANALYSIS OF SERIALY COLLECTED CIRCULATING TUMOR DNA (ctDNA) in OVARIAN CANCER PATIENTS**
Speaker: Yoo-Na Kim, MD
- 9. EVELUTION OF THE OVARINA CANCER TREATMENT PARADIGM, INCLUDING MAINTENANCE TREATMENT, IN THE US AND EUROPE: A REAL-WORLD CHART REWVIEW ANALYSIS (2017-2020)**
Speaker: Kathleen N. Moore, MD

10. KNOWLEDGE MEASURE FOR OVARIAN CANCER RESEARCH (KNOMOR): DEVELOPMENT AND PSYCHOMETRIC TESTING RESULTS OF A PATIENT-CENTERED KNOWLEDGE MEASURE

Speaker: Larissa A. Meyer, MD, MPH

11. DISTILLATION

Speaker: Michael A. Bookman, MD

12. DISTILLATION

Speaker: Elise C. Kohn, MD

FOCUSED PLENARY I: International Studies with Global Impact

Friday, March 18, 5:00 PM – 6:00 PM

PRESENTATIONS:

1. CLINICAL AND MOLECULAR CHARACTERISTICS OF AMBITION PATIENTS WHO RECEIVED OLAPARIB PLUS CEDIRANIB OR OLAPARIB PLUS DURVALUMAB FOR HOMOLOGOUS RECOMBINATION REPAIR MUTATED, PLATINUM-RESISTANT OVARIAN CANCER (KGOG 3045)

Speaker: Se Ik Kim, MD, PhD

2. ANLOTINIB IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OR -REFRACTORY OVARIAN CARCINOMA: A PROSPECTIVE, SINGLE-CENTER, SINGLE-ARM, PHASE II CLINICAL TRIAL

Speaker: Boer Shan, MD

3. DISTILLATION

Speaker: Isabelle Ray-Coquard, MD, PhD

4. Distillation

Speaker: Jerome L. Belinson, MD

5. LIO-1: INITIAL PHASE 2 EXPERIENCE OF LUCITANIB + NIVOLUMAB IN PATIENTS WITH METASTATIC OR RECURRENT CERVICAL CANCER (NCT04042116; ENGOT-GYN3/AGO/LIO)

Speaker: Ana Oaknin, MD, PhD

6. GENOMIC PROFILING AND PD-L1 EXPRESSION OF ADVANCED CERVICAL CANCER TO PREDICT RESPONSE TO PROGRAMMED DEATH-1 INHIBITOR COMBINATION THERAPY: A SECONDARY ANALYSIS OF THE CIBI308ALTER-C201 TRIAL

Speaker: Qin Xu, PhD

7. PENETRATING COMPLICATIONS OF BEVACIZUMAB-CONTAINING CHEMOTHERAPY IN PREVIOUSLY-IRRADIATED RECURRENT CERVICAL CANCER: A KOREAN MULTICENTER RETROSPECTIVE STUDY OF THE GYNECOLOGIC ONCOLOGY RESEARCH INVESTIGATORS

Speaker: Nam Kyeong Kim, MD

8. DISTILLATION

Speaker: Charles A. Leath, III, MD, MSPH

9. PILOT CERVICAL CANCER NAVIGATION PROGRAM OUTCOMES FROM A TERTIARY TANZANIAN ACADEMIC INSTITUTE

Speaker: Anjali Hari, MD

13. INTEGRATING CERVICAL CANCER SCREENING AND PREVENTION TREATMENT WITH VOLUNTARY FAMILY PLANNING IN MOZAMBIQUE

Speaker: Mila P. Salcedo, MD, PhD

FOCUSED PLENARY III: Inequities During the Pandemic and Beyond

Saturday, March 19, 9:00 AM – 10:30 AM

PRESENTATIONS:

1. IMPACT OF COVID-19 ON GYNECOLOGIC ONCOLOGY PATIENTS: AN SGO COVID-19 AND GYNECOLOGIC CANCER REGISTRY STUDY

Speaker: Gretchen E. Glaser, MD

2. WE CAN'T JUST WAIT THIS OUT: BURNOUT AND FULFILLMENT AMONG SGO MEMBERS OVER THE FIRST TWO WAVES OF THE COVID-19 PANDEMIC

Speaker: Caitlynn Carr, MD

3. PERSISTANT INEQUITIES IN ACCESS TO AND CONTINUITY OF GYNECOLOGIC ONCOLOGY CARE DURING THE COVID-19 PANDEMIC

Speaker: Shaina F. Bruce, MD

4. JUGGLING ACT: COVID-19'S IMPACT ON THE QUALITY OF LIFE OF GYNECOLOGIC ONCOLOGISTS

Speaker: Lia Bos, MD

5. GYNECOLOGIC ONCOLOGY PATIENTS LIVING IN RURAL AREAS LESS LIKELY TO UTILIZE TELEMEDICINE SERVICES DURING THE COVID-19 PANDEMIC

Speaker: Anna Kuan-Celarier, MD

6. PANDEMIC SOLUTIONS: THINGS HERE TO STAY

Speaker: Warner K. Huh, MD

7. REFUSAL OF GYNECOLOGIC CANCER SURGERY IS A SURGICAL AND ONCOLOGIC DISPARITY, NOT AN ISSUE OF NONCOMPLIANCE

Speaker: David Samuel, MD

8. DOES RACE IMPACT UTERINE CANCER SURGICAL TREATMENT: AN SGO CLINICAL OUTCOMES REGISTRY ANALYSIS

Speaker: Mona Saleh, MD

9. SOCIO-ECOLOGICAL MODEL OF BARRIERS TO CASCADE TESTING FOR HEREDITARY CANCER SYNDROMES: SYSTEMATIC REVIEW OF THE LITERATURE

Speaker: Xuan Li, MD

10. GEOSPATIAL APPROACHES FOR SURVEILLANCE OF DISPARITIES IN CLINICAL TRIAL ENROLLMENT

Speaker: Jennifer C. Gordon, MD

11. DISPARITIES IN THE QUALITY OF DEFINITIVE RADIATION THERAPY FOR PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER

Speaker: Dimitrios Nasioudis, MD

12. WHEN BEING INSURED IS NOT ENOUGH: THE EFFECT OF INSURANCE TYPE ON SURVIVAL IN CERVICAL CANCER

Speaker: Calen W. Kucera, MD, MPH, FACOG

13. RACE MATTERS: DISPARITIES IN THE USE OF MAINTENANCE THERAPY IN OVARIAN CANCER (OC)

Speaker: Evan A. Schrader, MD

14. DISTILLATION

Speaker: Nita K. Lee, MD, MPH

SCIENTIFIC PLENARY III: Novel Therapeutics: The Expanding Toolbox

Saturday, March 19, 11:00 AM – 12:15 PM

PRESENTATIONS:

1. PHASE 2, TWO-STAGE STUDY OF LETROZOLE AND ABEMACICLIB IN ESTROGEN RECEPTOR (ER) POSITIVE RECURRENT OR PERSISTENT ENDOMETRIAL CANCER

Speaker: Panagiotis A. Konstantinopoulos, MD, PhD

2. EGFL6 IS AN IMPORTANT GROWTH FACTOR INVOLVED IN ENDOMETRIAL CANCER TOMORIGENESIS

Speaker: Alison A. Garrett, MD

3. DISTILLATION

Speaker: Shannon N. Westin, MD, MPD

4. A NOVEL COMBO OF NIRAPARIB AND ANLOTINIB IN PLATINUM-RESISTANT OVARIAN CANCER, THE FINAL EFFICACY AND SAFETY REPORT OF ANNIE STUDY, A PHASE II, MULTI-CENTER TRIAL

Speaker: Ji Hong Liu

- 5. EFFICACY AND SAFETY OF SERPLULIMAB (AN ANTI-PD-1 ANTIBODY) COMBINED WITH ALBUMIN-BOUND PACLITAXEL IN PATIENTS WITH ADVANCED CERVICAL CANCER WHO HAVE PROGRESSIVE DISEASE OR INTOLERABLE TOXICITY AFTER FIRST-LINE STANDARD CHEMOTHERAPY**

Speaker: Jusheng An

- 6. EFFICACY AND SAFETY OF CADONILIMAB, AN ANTI-PD-1/CTLA4 bi specific antibody, in previously treated recurrent or metastatic (R/M) CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL**

Speaker: Xiaohua Wu

- 7. DISTILLATION**

Speaker: Nicoletta Colombo, MD, PhD

- 8. UPDATED RESULTS FROM THE PHASE 1 EXPANSION STUDY OF UPIFITAMAB RILSODOTIN (UPRI;XMT-1536) A NAPI2B-DIRECTED DOLAFLEXIN ANTIBODY DRUG CONJUGATE (ADC) IN OVARIAN CANCER**

Speaker: Debra L. Richardson, MD

- 9. CLINICAL OUTCOMES OF OVARIAN CANCER PATIENTS TREATED WITH THE NOVEL ENGINEERED CYTOKINE NEMVALEUKIN ALFA IN COMBINATION WITH THE PD-1 INHIBITOR PEMBROLIZUMAB: RECENT DATA FROM ARTISTRY-1**

Speaker: Ira S. Winer, MD, PhD

- 10. DISTILLATION**

Speaker: Katherine C. Fuh, MD, PhD

SCIENTIFIC PLENARY IV: Late-Breaking Abstracts

Saturday, March 19, 4:15 AM – 5:45PM

PRESENTATIONS:

- 12. A RANDOMIZED PHASE 3 TRIAL OF INTRAPERITONEAL VERSUS INTRAVENOUS CARBOPLATIN WITH DOSE-DENSE WEEKLY PACLITAXEL IN PATIENTS WITH OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CARCINOMA (A GOG-001/JGOG-3019/GCIG, IPOCC TRIAL)**

Speaker: Keiichi Fujiwara, MD, PhD

- 13. EFFICACY AND SAFETY OF MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR ALPHA EXPRESSION: RESULTS FROM THE SORAYA STUDY**

Speaker: Ursula A. Matulonis

- 14. DISTILLATION**

Speaker: Deborah K. Armstrong, MD

15. EFFICACY AND SAFETY OF NIRAPARIB AS MAINTENANCE TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER USING AN INDIVIDUALIZED STARTING DOSE (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial

Speaker: Ning Li, MD

16. PREDICTIVE VALUE OF THE LEUVEN HRD TEST COMPARED WITH MYRIAD MYCHOICE PLUS ON 468 OVARIAN CANCER SAMPLES FROM THE PAOLA-1/ENGOT-OV25 TRIAL

Speaker: Liselore Loverix, MD

17. THE GENOMIC LANDSCAPE OF LOW-GRADE SEROUS OVARIAN/PERITONEAL CARCINOMA (LGSOC) AND ITS IMPACT ON CLINICAL OUTCOMES

Speaker: David M. Gershenson, MD

18. GENOMIC ALTERATIONS, MOLECULARLY TARGETED THERAPY AND RACE: REAL WORLD DATA FROM THE ENDOMETRIAL CANCER MOLECULARLY TARGETED THERAPY CONSORTIUM

Speaker: Angeles Alvarez Secord, MD

19. DISTILLATION

Speaker: Barbara M. Noquist, MD

20. OPEN VS. MINIMALLY INVASIVE RADICAL HYSTERECTOMY IN EARLY CERVICAL CANCER: LACC TRIAL FINAL ANALYSIS

Speaker: Pedro T. Ramirez, MD

21. DISTILLATION

Speaker: Kristin L. Bixel, MD

22. PROSPECTIVE DOUBLE-BLIND, RANDOMIZED PHASE III ENGOT-EN5/GOG-3055/SIENDO STUDY OF ORAL SELINEXOR/PLACEBO AS AMINTENACE THERAPY AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER

Speaker: Ignace B. Vergote, MD, PhD

SPECIAL INTEREST SESSION: Curriculum for Emerging Clinical Trialists

Sunday, March 20, 7:00 AM – 10:00 AM

PRESENTATIONS:

1. STATISTICS FOR PHASE I TRIALS

Speaker: Jeanelle Sheeder, PhD

2. USING BIOMARKERS IN CERVICAL CANCER TRIALS

Speaker: Charles A. Leath, III, MD, MSPH

3. USING BIOMARKERS IN UTERINE CANCER TRIALS

Speaker: Angeles Alvarez Secord, MD

4. DESIGNING OVARY TRIALS IN THE ERA OF BIOMARKERS

Speaker: Kathleen N. Moore, MD

SCIENTIFIC PLENARY VI: Tumor Board – SGO Feud: Midwest Versus The Rest!

Sunday, March 20, 5:30 PM – 7:00 PM

PRESENTATIONS:

1. Tumor Board – SGO Feud: Midwest Versus The Rest!

Speaker: Kenneth H. Kim, MD, MHPE